Physician profile
Paul Palyca
NPI 1346545464
$351.60
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $55.54 · 2021: $11.92 · 2022: $65.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $75.57 | 2019 | |
| Incyte Corporation | $65.00 | 2022 | |
| Astellas Pharma US INC | $59.16 | 2019 | |
| Tactile Systems Technology INC | $20.83 | 2020 | |
| Abbvie INC. | $19.84 | 2020 | |
| Genentech USA, INC. | $15.88 | 2019 | |
| Lilly USA, LLC | $15.74 | 2019 | |
| Genzyme Corporation | $15.30 | 2019 | |
| Pfizer INC. | $14.87 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.75 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Merck Sharp & Dohme LLC | $11.75 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $10.99 | 2019 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Palyca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.